In dogs and cats proteinuria is a negative prognostic for chronic kidney disease and is associated with degree of functional impairment as well as the risk of a uremic crisis, progressive worsening of azotemia or death.
In dogs and cats proteinuria is a negative prognostic for chronic kidney disease and is associated with degree of functional impairment as well as the risk of a uremic crisis, progressive worsening of azotemia or death.
Normal dogs and most normal cats should have a urine protein:creatinine ratio that is <0. 4 and <0.2, respectively; persistent proteinuria above this magnitude warrants attention.
Administration of angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers is considered a standard of care in dogs and cats with renal proteinuria where the UPC is >0.5-1 and >0.2-0.4 respectively.
Blood pressure control and nutritional modification are also important considerations and part of the standard of care for dogs and cats with renal proteinuria.
Renal biopsy and administration of immunosuppressive agents should be considered in dogs with glomerular proteinuria that have not responded to standard therapy.
SYNOPSIS
Proteinuria is a negative prognostic indicator for dogs and cats with for chronic kidney disease and is associated with degree of functional impairment as well as the risk of a uremic crisis or death. The normal kidney is so highly efficient at preventing passage of proteins into the filtrate and reabsorbing the proteins that do get through that a normal dog or cat should excrete very little protein and have a urine protein:creatinine ratio that is <0.4 or <0.2, respectively; persistent proteinuria above this magnitude warrants attention.
Administration of angiotensin converting enzyme inhibitors (e.g., benazepril, enalapril) and/or angiotensin receptor blockers (e.g., telmisartan), blood pressure control and nutritional modification are considered a standard of care in dogs and cats with renal proteinuria. Renal biopsy and administration of immunosuppressive agents should be considered in dogs with glomerular proteinuria that have not responded to standard therapy; glomerular proteinuria is uncommon in cats. Targeted patient monitoring is essential when instituting management of renal proteinuria.
Proteinuria as a Prognostic Indicator in Chronic Kidney Disease
Proteinuria is a negative prognostic indicator for both dogs and cats with chronic kidney disease. In dogs with chronic kidney disease, an initial urine protein: creatinine ratio (UPC) of >1.0 was associated with a threefold greater risk of developing a uremic crisis and death (Jacob et al, 2005) . The relative risk of adverse outcomes increased 1.5 times for every increase in the UPC by 1. In another canine study, proteinuria correlated with the degree of functional impairment, as measured by glomerular filtration rate; dogs with UPC of <1.0 lived 2.7 times longer on average than dogs with a UPC >1.0 (Wehner et al, 2008 ).
When nonazotemic cats were prospectively and longitudinally evaluated, proteinuria was found to be significantly associated with the development of azotemia by 12 months (Jepson et al, 2009 ). Both proteinuria and serum creatinine were related to shortened survival in cats with chronic kidney disease (Syme et al, 2006; King et al, 2007 ).
This was true even when cats had UPC as low as 0.2-0.4.
Chronic proteinuria has been shown to be associated with interstitial fibrosis as well as tubular degeneration and atrophy, although the exact mechanisms of injury are a subject of debate (Toblli et Because proteinuria is associated with negative outcomes it is imperative that the practice veterinarian has a thorough understanding of appropriate assessment and management of proteinuria in dogs and cats with chronic kidney disease.
Normal Renal Handling of Protein
The glomerulus is a complex structure that functions as a filter, across which an ultrafiltrate of the plasma is formed. This filtration system, made up by the fenestrated endothelium, glomerular basement membrane and visceral epithelial cells (podocytes) is freely permeable to water and small dissolved solutes, but retains cells and most macromolecules, such as proteins. The podocyte is the most differentiated cell in the glomerulus and essential to the filtration unit (Tobilli et al, 2012) . In addition to these factors, glycocalyx has been found to play an important role in maintaining glomerular permselectivity by restricting the passage of proteins (Singh et al, 2007) . The major determinant of passage into the filtrate is molecular size. Low-molecular weight proteins, such as insulin and immunoglobulin fragments, pass freely through the filter, but as molecules increase in size they are retained with increasing efficiency. Only small amounts of substances larger than 60,000 to 70,000 daltons pass in to the filtrate. The podocyte foot processes, epithelial slits, basement membrane and endothelium are all rich in negatively charged glycoproteins that create an ionic charge barrier and impede the passage of negatively charged molecules more than would be expected based on their size alone.
Albumin, a negatively charged protein with a molecular weight of 69,000 daltons, is normally largely excluded from the filtrate. Despite this complex filtration system, the glomerulus normally leaks albumin. Rapid endocytosis and hydrolysis of these proteins by proximal tubular cells occurs. Filtered albumin and other proteins are ultimately released to the blood as amino acids. A normal animal should excrete virtually no protein in the urine, but certainly an amount that is below the limit of detection of routine urine protein assays (Maack, 2011) .
Laboratory Tests for Urine Protein
The urine dipstick, the sulfosalicylic turbidimetric test (SSA, bumin test) or the UPC can be used to measure total urine protein. The urine dipstick is the most readily available test of urine protein but is also the least reliable. Both false positives and false negatives occur. The sensitivity and specificity of the urine protein dipstick are as low as 54% and 69%, respectively, in the dog and 60% and 31%, respectively, in the cat. While the urine dipstick primarily detects albumin, it also measures globulins. The SSA is more reliable than the urine dipstick for the detection of proteinuria (both albumin and globulin); however, use of this test requires either having the appropriate reagents and standards on hand or sending the urine sample to a reference lab. The amount of protein that is present in the urine of normal dogs and cats is below the lower limit of detection for both of these tests. When both urine dipstick and SSA test results are available, the results of the SSA test should be given greater consideration than those of the urine dipstick. Positive results with either of these tests must be interpreted in light of the urine specific gravity.
Dogs and cats with repeat positive dipstick or SSA results in urine sample that is free of pyuria or a color change from hematuria should have urine protein losses quantified by the UPC. The UPC is determined using a quantitative test for total urine protein, the results of which are expressed as a ratio to urine creatinine thereby eliminating the need to consider the urine specific gravity when interpreting the results. The ratio correlates well with 24-hour urine protein losses and can be measured either in-house or as a send out test. Normal dogs, female cats and neutered male cats should have a UPC that is <0.2 (Table   1 ). Normal intact male cats can have UPC up to 0.6, most likely due to the excretion of large amounts of cauxin.
Persistent microalbuminuria is the mildest, and often earliest, detectable form of proteinuria. Urine albumin can be measured quantitatively through a commercial reference laboratory using a specifies-specific assay. The urine is diluted to a standard concentration (1.010) prior to assay, eliminating the need to consider urine specific gravity when interpreting the test results. Alternatively, some labs report urine albumin as a ratio to creatinine (i.e., mg albumin/g creatinine). Microalbuminuria is defined as concentrations of albumin in the urine that are greater than normal but below the limit of detection using the urine dipstick. By this definition, the upper end of urine albumin concentrations that are still considered to be microalbuminuria is 30 mg/dl (or 300 mg albumin/g creatinine).
Urine albumin concentrations above this are called overt albuminuria. Proteinuria of this magnitude can often be detected using the UPC.
Clinical Assessment of Proteinuria
Accurate assessment of proteinuria involves 3 key elements: persistence, localization, and magnitude (Lees et al, 2005) . Persistent proteinuria is defined as proteinuria that has been detected on 3 or more occasions, 2 or more weeks apart.
Persistent proteinuria should be localized as being pre-renal, post-renal, or renal ( Table 2 ).
Identifying the cause of proteinuria in an affected dog or cat is important so that appropriate therapeutic measures can be implemented. Renal proteinuria that is glomerular or tubulointerstitial in origin is the most relevant form of proteinuria when managing dogs with chronic kidney disease. However, it is important to ensure that proteinuria is not due to pre-renal or post-renal causes because the management of these disorders varies substantially from the management of chronic kidney disease. Functional proteinuria is not very common in dogs and cats, or at least poorly documented.
Once pre-renal and post-renal causes of persistent proteinuria are eliminated, magnitude is used to help determine if renal proteinuria is glomerular or tubulointerstitial in origin. Magnitude is assessed using a quantitative test for urine protein (generally UPC but could also be urine albumin). Once pre-renal and post-renal causes of proteinuria have been excluded, it is recommended that a UPC be evaluated in all dog and cats with persistent proteinuria as determined by dipstick or SSA.
The International Renal Interest Society (IRIS) has recommended substaging dogs and cats with chronic kidney disease on the basis of their UPC ( Table 1 
Inhibition of RAAS to Manage Proteinuria
Hemodynamic forces influence the transglomerular movement of proteins and it follows that altering renal hemodynamics would be effective in reducing proteinuria (Brown et al, 2013) . The renin-angiotensin-aldosterone system (RAAS) has been the major target system for this approach to reducing proteinuria ( Figure 1 ). Agents that target RAAS include the angiotensin converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), and aldosterone receptor antagonists (Table 3) . Although renin inhibitors are being used in people, they have not been used to any great extent in dogs and cats. All RAAS inhibitors have antihypertensive effects although most of them only minimally reduce blood pressure (i.e., 10-15%). These drugs likely reduce proteinuria by several mechanisms in addition to the expected decrease in glomerular capillary hypertension.
Likewise, the reduction in proteinuria is greater than would be expected on the basis of their antihypertensive effects alone. RAAS inhibition is considered a standard of care in dogs and cats with renal proteinuria where the UPC is >0.5-1 and >0.2-0.4 respectively. The inhibitors of RAAS reduce proteinuria in populations of animals but the effect in individual animals might vary. It may take trial and error with different drugs or combinations of drugs before the target antiproteinuric effect is achieved (see Monitoring Drug Therapy below); some animals may never achieve target reductions.
Angiotensin Converting Enzyme Inhibitors
ACEi administration has been associated positive outcomes in dogs, cats and people with chronic kidney disease (Grauer et (Grauer et al, 2015) . In dogs with partial nephrectomies, enalapril treated dogs had a reduction in glomerular and tubulointerstitial lesions following 6 months of treatment (Brown et al, 2003) . Likewise, dogs with chronic kidney disease that were given benazepril had higher glomerular filtration rates and lower UPCs when compared to a placebo-treated group (Tenhundfeld et al, 2009 ).
In cats, benazepril administration was associated with reduced glomerular capillary pressure in cats with induced chronic kidney disease (Brown et al, 2001 ). In cats with naturally occurring chronic kidney disease, benazepril was associated with a reduction in proteinuria, even in the subgroup of cats with initial UPC of <0. Initially an ACEi is given once daily, but more than half of the dogs will need twice daily administration eventually and perhaps additional dosage escalations ( Figure 2 ) (Grauer et al, 2000) . Many veterinarians are concerned about administering an ACEi to a dog or cat that is already azotemic. In people, the renoprotective effects of ACEi are independent of the baseline renal function and ACEi slowed progressive disease even in patients with severe renal failure (Ryan and Tuttle, 2008) . In reality, it seems to be uncommon for dogs and cats to have severe worsening of azotemia (i.e., >30% increase from baseline) due to ACEi administration alone provided animals are clinically stable prior to the introduction of these agents. Dogs that are dehydrated may be at highest risk for worsening of azotemia after initiating ACEi therapy; euvolemia should be achieved before initiating an ACEi to these patients. Furthermore, some caution is warranted when administering an ACEi to a dog or cat in late stage 3 or stage 4 CKD (e.g., low initial starting dose with small incremental increases).
Many veterinarians wonder if one drug is better than another in animals with reduced renal function. The pharmacokinetics of ACEi are complicated and the effects of disease on the pharmacodynamics of these drugs in not necessarily predictable. There is no scientific basis to support that one ACEi has superior pharmacodynamic action. Benazepril and its active metabolite, benazeprilat, are largely eliminated by the biliary route with a smaller fraction being excreted in the urine; impaired renal function does not affect the clearance of this drug in dogs (Lefebvre et al, 1999) . On the other hand, enalapril and its active metabolite, enalaprilat, are primarily eliminated by the kidney. Animals in IRIS late stage 3 or stage 4 CKD may require a lower dosage of enalapril to achieve target antiproteinuric effects.
Angiotensin Receptor Blockers
ARBs block the angiotensin II type 1 receptor. Several ARBs have been studied extensively in people with glomerular disease and lead to a reduction in proteinuria similar to that which is seen with ACEi. People treated with losartan had an average reduction in proteinuria of 35% from baseline during a 3.4 year follow up period; much of this reduction was in the first 6 months of therapy (Bakris et al, 2008) . In irbesartan treated patients, every 50% reduction in proteinuria during the first 12 months of therapy reduced the risk of a negative renal outcome by more than half (Bakris et al, 2008 ).
The use of ARBs in dogs and cats with proteinuric chronic kidney disease is still being developed. The one that seems to be the most effective is telmisartan; however, losartan has been used more extensively (Sent et al, 2015; Bugbee et al, 2014) . Even though dogs do not appear to produce one of the major active metabolites of losartan, there is good evidence that losartan exerts pharmacodynamic effects in dogs (Christ et al, 1992 ).
Contrary to this, pharmacodynamic studies suggest that losartan may not be effective in cats, at least in attenuation of pressor responses (Jenkins et al, 2015) .
Telmisartan is more lipophilic, and has a longer half-life than losartan; its blocking effects persist for longer than would be predicted from its plasma half-life. Furthermore, it has a higher affinity for, and dissociates more slowly from, the angiotensin-1 receptor.
Therefore, it is not surprising that telmisartan was shown to be more effective in reducing Indeed, telmisartan reduced UPC relative to the pre-treatment value at all time points evaluated in the 6-month trial whereas benazepril only reduced UPC at very early time points (Sent et al, 2015) .
Combined Therapy with ACEi and ARB
There may be an added benefit to combined administration of an ACEi and an ARB because of the inability of either class of drug to provide complete RAAS blockade when Combination therapy increases the degree of blockade, but it is still may not be more than 75-80% complete.
Serum aldosterone increases over time in some people treated even with maximal dosages of RAAS inhibitors, a phenomenon referred to as aldosterone breakthrough. The incidence of aldosterone breakthrough in people treated with RAAS inhibitors for chronic kidney disease, systemic hypertension or heart failure is between 10 and 53% (Bomback and Klemmer 2007). Prolonged hyperaldosteronism can have adverse effects on the heart, systemic blood vessels and glomeruli. Therefore, it is not surprising that some people that experience aldosterone breakthrough during treatment for various glomerular diseases 
Monitoring Drug Therapy
The UPC, urinalysis, systemic blood pressure and serum albumin, creatinine and potassium concentrations (in fasting samples) should be monitored at least quarterly in all animals being treated for proteinuric renal disease. However, those that are having new drugs introduced or dosage modifications being made for drugs already being administered should be monitored more frequently (Figure 2 ). One to 2 weeks after an ACEi or ARB is added or changed, the UPC, serum creatinine, serum potassium and systemic blood pressure should be evaluated to verify that the recent change in therapy has not resulted in a severe worsening of renal function (i.e., >30% increase in serum creatinine), a concerning increase in serum potassium concentrations, or hypotension (an unlikely occurrence with these drugs). 
Day-to-day variations in the UPC

Making Therapeutic Adjustments for RAAS Inhibitors
An ACEi is the initial therapy in most dogs and cats with proteinuria, with the typical starting dosage of 0.5 mg/kg q24h (Figure 2) . However, the ARB telmisartan may soon become a reasonable alternative for an initial agent. In dogs and cats, the ideal therapeutic target is a reduction in the UPC to <1 without inappropriate worsening of renal function. Whereas RAAS inhibitors can be used in this subset of patients, the initial starting doses and incremental dose increases should be very low and renal function should be monitored closely; therapeutic adjustments may be needed to maintain baseline renal function.
Because this ideal target is not achieved in most animals
If the target reduction in UPC is not achieved, the plasma potassium concentration is <6 and any changes in renal function fall within the tolerable limit, dosages may be increased every 4-6 weeks. If the target reduction in UPC is not achieved with a maximal dosage an ACEi, the next step should be to add an ARB. Alternatively an ARB can be used as monotherapy in dogs who appear to be intolerant of an ACEi.
Managing Hyperkalemia
Hyperkalemia appears to be a common side effect of RAAS inhibition in dogs with kidney disease but is probably uncommon in cats. Pseudohyperkalemia, often associated with thrombocytosis, can also occur in dogs and needs to be ruled-out by measuring the potassium concentration in lithium heparin plasma before taking further action. Because of the cardiotoxic effects of potassium, dogs or cats with true hyperkalemia of > 5.5 mEq/L should be monitored closely; therapy should be modified if serum potassium concentrations are >6 to 6.5 mEq/L. When plasma potassium concentrations are >6mEq/L, an ECG should be evaluated for cardiac conduction disturbances. True hyperkalemia can be managed by reducing the ACEi or ARB drug dosage, discontinuing spironolactone administration, or by feeding diets that are reduced in potassium (note that renal diets may be supplemented with potassium). The use of an intestinal potassium binder (e.g., kayexelate) has been limited in dogs. Rarely hyperkalemia would be severe enough to warrant hemodialysis. Potassium-reduced home-prepared diets that were formulated by a veterinary nutritionist have been shown to effectively correct hyperkalemia long-term in dogs with chronic kidney disease (Segev et al, 2010 ).
Management of Hypertension
The kidney is one of the target organs for hypertensive damage and sustained hypertension may lead to an increased magnitude of proteinuria, rate of decline of renal function, frequency of uremic crises and mortality (Jepson et al, 2009 , Finco et al, 2004 Brown et al, 2007) . The goal of antihypertensive therapy is to reduce the blood pressure so that the risk of continued target organ damage is minimized (Table 4) . Inhibitors of RAAS are generally only weak antihypertensive agents, leading to a reduction in blood pressure by only about 10-15%. Dogs and cats that have sustained systolic blood pressures ≥160 mmHg while being administered a RAAS inhibitor have a moderate to high risk of future target organ damage and may need additional therapeutic consideration. In these animals, the first step is to increase the dose of the RAAS inhibitor. If the upper end of the dosage range is being administered and the risk of target organ damage remains moderate to high, the next step is to add a calcium channel blocker. Amlodipine is usually used with a starting dose of 0.2-0.4 mg/kg q24 hours but can be incrementally increased to a total daily dose of 0.75 mg/kg, which can be divided to q12h. There is evidence that amlodipine will activate the RAAS system; therefore it should not be used as monotherapy for the management of hypertension in dogs . However in cats monotherapy may be more appropriate because giving multiple drugs is harder, amlodipine alone may bring the UPC down to <0.2 in hypertensive cats and amlodipine-induced increases in plasma renin activity are not associated with an increase in aldosterone in cats (Jepson et al, 2014 ).
Systolic blood pressure should be monitored during therapy and maintained >120 mmHg in treated dogs and cats. High salt intake should be avoided although salt restriction alone will not adequately reduce blood pressure.
Diet
In animal models of chronic kidney disease, the magnitude of proteinuria can be reduced by dietary modification -specifically by modifying the polyunsaturated fatty acid ratio and protein content (Brown et al, 2013) . Dietary supplementation with n-3 polyunsaturated fatty acids or feeding a diet that has a reduced n-6/n-3 ratio that is close to 5:1, as found in most commercially available renal diets is expected to alter the long term course of renal injury and reduce the magnitude of proteinuria. It is generally accepted that feeding a renal diet that is modified in protein content reduces intraglomerular pressure as well as the magnitude of proteinuria and the generation of uremic toxins. However, the magnitude of this reduction in proteinuria is small. Renal diet alone should not be expected to adequately reduce proteinuria in most animals.
Renal Biopsy
Nearly 60% of dogs with glomerular proteinuria will have either immune-complex mediated glomerulonephritis or amyloidosis (Schneider et al, 2013) , both of which may represent an aberrant or excessive immune or inflammatory response to an infectious, neoplastic or inflammatory condition. Cats rarely get glomerulonephritis but a percentage of these cats would also be expected to have developed this secondary to a systemic disease. Therefore, in dogs or cats with glomerular proteinuria it is indicated to pursue extended diagnostic testing, the extent of which might vary depending upon patient characteristics and potential exposure to regional infectious agents (Littman et al, 2013) . It is possible that complete or partial resolution of proteinuria will follow successful treatment of any causative systemic diseases.
Renal biopsy should be considered in animals with persistent glomerular range proteinuria that do not have any contraindications to renal biopsy and have not responded to standard therapy (Littman et al, 2013) . Some of the more common contraindications to biopsy include chronic kidney disease with serum creatinine >5 mg/dL, uncontrolled hypertension, pyelonephritis, renal cystic disease, coagulopathy, hydronephrosis, and severe anemia. When biopsy samples are processed correctly, clinical decisions regarding the diagnosis, treatment, and prognosis can be made from the information obtained through renal biopsy in dogs. Experienced personnel should be involved with procuring, preparing and interpreting the renal biopsy that has been processed for light, electron, and immunofluorescence microscopy. 
Immunosuppressive Agents
Empirical administration of immunosuppressive or anti-inflammatory therapy has been recommended for dogs that have no known contraindications for the specific drugs being considered and have severe, persistent, or progressive glomerular disease in which there is renal biopsy-supported evidence of immune-mediated pathogenesis (Segev et al, 2013) . Dogs with more severe disease or rate of progression should be treated more aggressively than those with more stable disease. Single agent or combination therapy for rapid onset of immunosuppression should be considered in dogs with high magnitude proteinuria with hypoalbuminemia, NS, or rapidly progressive azotemia (Segev et al, 2013) .
Mycophenolate, or cyclophosphamide, with or without short-term administration of glucocorticoids, has been suggested as the first choice. Glucocorticoids should be limited to short-term therapy because of the potential association with corticosteroid excess and proteinuria. Dogs with stable or more slowly progressive disease that have only partial or no response to standard therapy might be given drugs that have a either a rapid or a more delayed onset of drugs, such as mycophenolate, chlorambucil or cyclophosphamide.
Cyclosporine has also been suggested as a first choice for stable or slowly progressive dogs.
It is important to note that this is the only drug that has been studied prospectively in dogs with glomerular disease and was found to be of no benefit, although there were flaws in the design of that study (Vaden et al, 2995) . 
